Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 4995
Single User License Price INR 344655
Corporate User License Price USD 14985
Corporate User License Price INR 1033965
Site License Price USD 9990
Site License Price INR 689310
Request a Quote

Report Title

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

Quote Request for License Type
License Type Price  
Single User License USD 4995
Site License USD 9990
Enterprise Wide License USD 14985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies


Quote Request for License Type
License Type Price  
Single User License USD 4995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies



Executive Summary

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024-Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

Summary

Atopic dermatitis (AD), also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with a characteristic phenotype and typically distributed skin lesions.

It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults globally. AD is a genetically complex, familial transmitted disease with a strong maternal influence; a child possesses a two-fold risk of developing the disease if one of the parents is affected and a three-fold risk if both are affected. Many studies reported that increasing urbanization, westernization of lifestyle, obesity, lack of physical exercise, stress, food allergies, and pollution increase the risk of AD.

The current marketed drug landscape in AD includes topical agents (corticosteroids and calcineurin inhibitors), systemic therapies (such as corticosteroids, cyclosporine, azathioprine, methotrexate and mycophenolatemofetil) and a biologic therapy (Dupixent). Topical steroids have been the mainstay of treatment for AD in both children and adults for the past half century.

The evolution in the understanding of the pathogenesis of AD has led to the discovery and development of several promising treatment options for AD. Recently, two new therapies have been approved for AD, Eucrisa (crisaborole) and Dupixent (dupilumab). However, currently Sanofi/Regeneron'sDupixent is the only targeted therapy that is available in Southeast Asia AD market.

The late-stage AD pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period. These include LEO Pharma'stralokinumab, Eli Lilly's baricitinib, Kangstem Biotech's furestem-AD, Pfizer's PF-04965842 and Amorepacific's PAC-14028. These new drugs will expand the options available to treat AD patients and contribute to overall market growth by offering novel treatment mechanisms.

Scope

- The Southeast Asia AD market will be valued at USD 848.6m in 2024, growing from USD 423.2m in2017, at a compound annual growth rate of 10.5%.

- What are the key factors driving the Southeast Asia AD treatment market?

- What classes of drugs dominate the market?

- How will the market respond to recent approval?

- How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?

- The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.

- Which classes of novel drugs are most prominent in the pipeline?

- What are the common targets and mechanisms of action of pipeline therapies?

- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

- How have the late-stage therapies performed in clinical trials?

- What are the commercial prospects for the most promising late-stage products?

- How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?

- Various drivers and barriers will influence the market over the forecast period.

- Which factors are most likely to drive the market in these countries?

- What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy

This report will enable you to:

- Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.

- Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.

- Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.

- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

- Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising late-stage molecules to market growth.

- Discover trends in licensing and co-development deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 11

2.1 Disease Introduction 11

2.2 Epidemiology 11

2.3 Symptoms 12

2.4 Etiology and Pathophysiology 13

2.4.1 Etiology 13

2.4.2 Pathophysiology 14

2.5 Diagnosis 15

2.5.1 Hanifin and Rajka Diagnostic Criteria 15

2.5.2 UK Working Party's Diagnostic Criteria 16

2.5.3 Biomarkers 16

2.6 Classification and Disease Stages 16

2.7 Prognosis 17

2.8 Treatment Options and Guidelines 17

2.8.1 Emollients 17

2.8.2 Topical corticosteroids 17

2.8.3 Topical calcineurin inhibitors 17

2.8.4 Antimicrobials 18

2.8.5 Systemic immunosuppressive therapy 18

2.8.6 Biologics 18

2.8.7 Other treatments 18

2.8.8 Wet wrap therapy 18

2.9 Treatment guidelines 19

3 Marketed Products 21

3.1 Overview 21

3.1.1 Dupixent (dupilumab)-Regeneron and Sanofi 21

3.1.2 Protopic (tacrolimus)-Astellas 23

3.1.3 Elidel (Pimecrolimus)-Novartis 25

3.1.4 Cyclosporine 26

3.1.5 Xolair (omalizumab)-Novartis and Genentech (Off-Label Therapy) 27

3.1.6 Eucrisa (crisaborole)-Pfizer 28

3.1.7 Other Therapeutic Drug Classes Used in Atopic Dermatitis 29

3.2 Comparative Efficacy and Safety of Marketed Products 30

4 Pipeline Analysis 33

4.1 Overview 33

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 34

4.3 Pipeline by Molecular Target 36

4.4 Promising Pipeline Candidates 38

4.4.1 Tralokinumab-LEO Pharma 38

4.4.2 Furestem-AD-Kang Stem Biotech 39

4.4.3 Baricitinib-Eli Lilly and Incyte Corporation 41

4.4.4 PAC-14028- Amorepacific 42

4.4.5 PF-04965842-Pfizer 43

4.5 Comparative Efficacy and Safety of Pipeline Products 43

4.6 Product Competitiveness Framework 45

5 Clinical Trial Analysis 47

5.1 Failure Rate 47

5.1.1 Overall Failure Rate 47

5.1.2 Failure Rate by Phase and Molecule Type 48

5.1.3 Failure Rate by Phase and Molecule Target 49

5.2 Clinical Trial Size 50

5.2.1 Patient Enrollment per Trial by Molecule Type and Stage of Development 50

5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 51

5.2.3 Patient Enrollment per Product by Molecule Type and Stage of Development 52

5.2.4 Patient Enrollment per Product by Molecular Target and Stage of Development 53

5.3 Clinical Trial Duration 54

5.3.1 Clinical Trial Duration by Molecule Type 54

5.3.2 Clinical Trial Duration by Molecular Target 55

5.4 Competitive Clinical Trials Metrics Analysis 56

6 Multi-scenario Forecast 58

6.1 Geographical Market 58

6.2 Southeast Asian Markets 58

6.3 South Korea 61

6.3.1 Treatment Usage Patterns 61

6.3.2 Annual Cost of Therapy 62

6.3.3 Market Size 63

6.4 Singapore 64

6.4.1 Treatment Usage Patterns 64

6.4.2 Annual Cost of Therapy 65

6.4.3 Market Size 66

6.5 Taiwan 67

6.5.1 Treatment Usage Patterns 67

6.5.2 Annual Cost of Therapy 68

6.5.3 Market Size 69

6.6 Malaysia 70

6.6.1 Treatment Usage Patterns 70

6.6.2 Annual Cost of Therapy 71

6.6.3 Market Size 72

6.7 Philippines 73

6.7.1 Treatment Usage Patterns 73

6.7.2 Annual Cost of Therapy 73

6.7.3 Market Size 74

6.8 Thailand 75

6.8.1 Treatment Usage Patterns 75

6.8.2 Annual Cost of Therapy 76

6.8.3 Market Size 77

6.9 Vietnam 78

6.9.1 Treatment Usage Patterns 78

6.9.2 Annual Cost of Therapy 79

6.9.3 Market Size 80

6.10 Indonesia 80

6.10.1 Treatment Usage Patterns 80

6.10.2 Annual Cost of Therapy 81

6.10.3 Market Size 82

7 Drivers and Barriers 84

7.1 Drivers 84

7.1.1 Increasing awareness and diversified healthcare reform to boost market growth 84

7.1.2 Promising pipeline products that target unmet needs for AD 84

7.1.3 Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 84

7.2 Barriers 85

7.2.1 First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 85

7.2.2 Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 85

7.2.3 The complexity of the multiple etiologies that lead to AD means that treatment outcomes with existing drugs are not universal across all patient groups 85

8 Deals and Strategic Consolidations 86

8.1 Licensing Deals 86

8.1.1 Deals by Region and Value 86

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 87

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87

8.1.4 Key Licensing Deals 90

8.2 Co-development Deals 91

8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target 91

8.2.2 Key Co-development Deals 92

9 Appendix 93

9.1 All Pipeline Drugs by Stage of Development 93

9.1.1 Discovery 93

9.1.2 Preclinical 94

9.1.3 Phase I 96

9.1.4 Phase II 97

9.1.5 Phase III 98

9.2 Summary of Multi-Scenario Market Forecasts to 2024 99

9.2.1 Southeast Asia 99

9.2.2 South Korea 99

9.2.3 Singapore 100

9.2.4 Taiwan 100

9.2.5 Malaysia 101

9.2.6 Philippines 101

9.2.7 Thailand 102

9.2.8 Vietnam 102

9.2.9 Indonesia 103

9.3 Bibliography 103

9.4 Abbreviations 108

9.5 Research Methodology 109

9.5.1 Secondary Research 110

9.5.2 Marketed Product Profiles 110

9.5.3 Late-Stage Pipeline Candidates 110

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 110

9.5.5 Product Competitiveness Framework 111

9.5.6 Pipeline Analysis 111

9.5.7 Forecasting Model 111

9.5.8 Deals Data Analysis 112

9.6 Contact Us 113

9.7 Disclaimer 113

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Atopic Dermatitis Therapeutics, South Korea, Age-Specific Prevalence (%), 2012 12

Figure 2: Prevalence of Atopic Dermatitis Associated Symptoms 13

Figure 3: Treatment Algorithm for Atopic Dermatitis Based on Severity 20

Figure 4: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Atopic Dermatitis 32

Figure 5: Atopic Dermatitis Therapeutics Market, Global, Overview of Pipeline Products, 2018 35

Figure 6: Atopic Dermatitis Therapeutics Market, Global, Pipeline by Molecular Target, 2018 37

Figure 7: Atopic Dermatitis Therapeutics Market, Southeast Asia, Tralokinumab, Market Forecast (USD m), 2021-2024 39

Figure 8: Atopic Dermatitis Therapeutics Market, Southeast Asia, Furestem-AD, Market Forecast (USD m), 2021-2024 40

Figure 9: Atopic Dermatitis Therapeutics Market, Southeast Asia, Baricitinib, Market Forecast (USD m), 2020-2024 42

Figure 10: Atopic Dermatitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 45

Figure 11: Atopic Dermatitis Therapeutics Market, Competitor Matrix for AD Marketed and Pipeline Products 46

Figure 12: Atopic Dermatitis Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2007-2018 48

Figure 13: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2018 49

Figure 14: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2018 50

Figure 15: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2018 51

Figure 16: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2018 52

Figure 17: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2018 53

Figure 18: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2018 54

Figure 19: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2007-2018 55

Figure 20: Atopic Dermatitis Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2007-2018 56

Figure 21: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 56

Figure 22: Atopic Dermatitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 57

Figure 23: Atopic Dermatitis Therapeutics Market, Southeast Asia, Treatment Usage Pattern (million), 2017-2024 59

Figure 24: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Size (USD m), 2017-2024 60

Figure 25: Atopic Dermatitis Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2017-2024 62

Figure 26: Atopic Dermatitis Therapeutics Market, South Korea, Annual Cost of Therapy (USD ), 2017-2024 63

Figure 27: Atopic Dermatitis Therapeutics Market, South Korea, Market Size (USD m), 2017-2024 64

Figure 28: Atopic Dermatitis Therapeutics Market, Singapore, Treatment Usage Patterns (million), 2017-2024 65

Figure 29: Atopic Dermatitis Therapeutics Market, Singapore, Annual Cost of Therapy (USD ), 2017-2024 66

Figure 30: Atopic Dermatitis Therapeutics Market, Singapore, Market Size (USD m), 2017-2024 67

Figure 31: Atopic Dermatitis Therapeutics Market, Taiwan, Treatment Usage Patterns (million), 2017-2024 68

Figure 32: Atopic Dermatitis Therapeutics Market, Taiwan, Annual Cost of Therapy (USD ), 2017-2024 69

Figure 33: Atopic Dermatitis Therapeutics Market, Taiwan, Market Size (USD m), 2017-2024 70

Figure 34: Atopic Dermatitis Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2017-2024 71

Figure 35: Atopic Dermatitis Therapeutics Market, Malaysia, Annual Cost of Therapy (USD ), 2017-2024 72

Figure 36: Atopic Dermatitis Therapeutics Market, Malaysia, Market Size (USD m), 2017-2024 72

Figure 37: Atopic Dermatitis Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2017-2024 73

Figure 38: Atopic Dermatitis Therapeutics Market, Philippines, Annual Cost of Therapy (USD ), 2017-2024 74

Figure 39: Atopic Dermatitis Therapeutics Market, Philippines, Market Size (USD m), 2017-2024 75

Figure 40: Atopic Dermatitis Therapeutics Market, Thailand, Treatment Usage Patterns (million), 2017-2024 76

Figure 41: Atopic Dermatitis Therapeutics Market, Thailand, Annual Cost of Therapy (USD ), 2017-2024 77

Figure 42: Atopic Dermatitis Therapeutics Market, Thailand, Market Size (USD m), 2017-2024 78

Figure 43: Atopic Dermatitis Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2017-2024 79

Figure 44: Atopic Dermatitis Therapeutics Market, Vietnam, Annual Cost of Therapy (USD ), 2017-2024 79

Figure 45: Atopic Dermatitis Therapeutics Market, Vietnam, Market Size (USD m), 2017-2024 80

Figure 46: Atopic Dermatitis Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2017-2024 81

Figure 47: Atopic Dermatitis Therapeutics Market, Indonesia, Annual Cost of Therapy (USD ), 2017-2024 82

Figure 48: Atopic Dermatitis Therapeutics Market, Indonesia, Market Size (USD m), 2017-2024 83

Figure 49:Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018 86

Figure 50: Atopic Dermatitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 87

Figure 51: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 88

Figure 52: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 89

Figure 53: Atopic Dermatitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value (USD ), 2007-2018 90

Figure 54:Atopic Dermatitis Therapeutics Market, Global, Co-development Deals by Region, 2007-2018 92

1.1 List of Tables

Table 1: Hanifin and Rajka Diagnostic Criteria 15

Table 2: UK Working Party's Diagnostic Criteria 16

Table 3: Classification of Atopic Dermatitis Based on Severity, Symptoms and Impact on Quality of Life 16

Table 4: Atopic Dermatitis Therapeutics, Southeast Asia, Summary of Other Therapeutic Classes for Atopic Dermatitis 30

Table 5: Atopic Dermatitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2007-2018 91

Table 6: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 93

Table 7: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 94

Table 8: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 96

Table 9: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 97

Table 10: Atopic Dermatitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 98

Table 11: Atopic Dermatitis Therapeutics Market, Southeast Asia, Market Forecast, 2017-2024 99

Table 12: Atopic Dermatitis Therapeutics Market, South Korea, Market Forecast, 2017-2024 99

Table 13: Atopic Dermatitis Therapeutics Market, Singapore, Market Forecast, 2017-2024 100

Table 14: Atopic Dermatitis Therapeutics Market, Taiwan, Market Forecast, 2017-2024 100

Table 15: Atopic Dermatitis Therapeutics Market, Malaysia, Market Forecast, 2017-2024 101

Table 16: Atopic Dermatitis Therapeutics Market, Philippines, Market Forecast, 2017-2024 101

Table 17: Atopic Dermatitis Therapeutics Market, Thailand, Market Forecast, 2017-2024 102

Table 18: Atopic Dermatitis Therapeutics Market, Vietnam, Market Forecast, 2017-2024 102

Table 19: Atopic Dermatitis Therapeutics Market, Indonesia, Market Forecast, 2017-2024 103

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person